Oracle


ORCL

is working with Oxford Nanopore Technologies to advance the reach of DNA/RNA sequencing technology to boost the identification and treatment of new and existing diseases. Subject to regulatory and customary conditions, the company will also invest £150 million in Oxford Nanopore.

The companies will utilize Oracle Cloud Infrastructure (OCI) to run genome sequencing and develop various new medical solutions to enhance patient care outcomes. Oxford Nanopore will implement OCI in applied and clinical markets, noted Oracle.

By using OCI, Oxford Nanopore can expand its “population-scale” genetic sequencing technology worldwide, stated Oracle. The companies will work together to foster advances in epidemiology, whole-genome sequencing and drug development research.

Oracle will also integrate Oxford Nanopore’s DNA/RNA sequencing technology and data with its healthcare and life sciences solutions/applications portfolio.

Oxford Nanopore, based in the U.K., specializes in scalable and accessible nanopore sequencing technology. This technology, at present, is leveraged by scientists in more than 100 countries to gain a better understanding of human and cancer genetics, pathogen analysis (including COVID-19, Zika, Ebola and Lassa fever) as well as plant, animal and environmental studies, added Oracle.

Need for Cloud Services in Healthcare Bodes Well

Global healthcare cloud computing market is expected to witness a CAGR of 14.1% between 2021 and 2026,

according to a Mordor Intelligence report.

The coronavirus crisis is driving the digital transformation of the entire healthcare system. This is forcing healthcare companies to rapidly digitize their operations to ensure business continuity. Cloud services offer healthcare providers with enhanced scalability as well as simplified data storage and accessibility.

Apart from increasing telehealth services, the healthcare cloud computing market is being driven by the adoption of innovative technologies like machine learning, AI, Internet of Things (IoT) and big data analytics in healthcare as well as growing proliferation of smart wearable devices.

These projections highlight huge revenue growth opportunities for cloud service providers like Oracle. Oracle is fast gaining ground in the lucrative cloud domain. The company’s software-as-a-service (SaaS), infrastructure-as-a-service (IaaS) and platform-as-a-service (PaaS) products are likely to grow strongly over the next few years as enterprises transition to the cloud.

In the first quarter of fiscal 2022

, management noted that the company’s IaaS and SaaS business accounted for 25% of total quarterly revenues with an annual run rate of $10 billion.

The next-generation autonomous database rolled out by Oracle, which is supported by machine learning (ML), is gaining significant momentum. Autonomous database in Gen2 public cloud infrastructure is also witnessing healthy uptake.

Oracle’s Cloud services and license support revenues (nearly 76% of total revenues) in the last reported quarter increased 6% year over year (up 5% at cc) to $7.371 billion. The upside can be attributed to continued strength in the Fusion, Autonomous Database and OCI services.

Increased availability of Oracle cloud regions globally is consolidating its competitive position in the cloud computing market. The company currently has 30 cloud regions in the world.

However, higher spend on product enhancements, especially toward cloud platform, amid increasing competition in the cloud domain from the established players like

Amazon


AMZN

,

Microsoft


MSFT

and

Alphabet

’s

GOOGL

Google Cloud is likely to limit margin expansion, in the near term.

Oracle currently carries a Zacks Rank #3 (Hold). You can see


the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research